Introduction: Hepcidin is a regulatory protein in iron metabolism; we do not know the role in chronic kidney disease anemia. Methods: 22 patients with CKD anemia and 15 patients with CKD without anemia were investigated. CKD anemia-inclusion criteria: over 18 years, hemoglobin ≤12 g/dl for women and ≤13 g/dl for men, no treatment for anemia 6 months before enrollment, glomerular filtration rate (eGFR) <60 ml/min/1.73m2 and stable creatinine three months before enrollment. Exclusion criteria: infection, bleeding, malignancy, systemic or liver disease, immunosuppression, renal replacement therapy. CKD without anemia-inclusion criteria: over 18 years, no anemia or treatment for anemia, CKD with stable creatinine values three months before enrollment. Exclusion criteria: medical conditions known to have a role in the development of polycythemia. Hepcidin-25 and ferritin were measured by ELISA method. Erythropoietin (EPO), tumor necrosis factor (TNF)-α, interleukin (IL)-6 were evaluated using chemiluminescent enzyme immunometric assays. Unpaired T test, Pearson correlation and multiple regression were used for statistical analysis. Results: Hemoglobin values were significantly lower in anemia group. There were no differences in terms of eGFR, age, body mass index, serum hepcidin, erythropoietin, fibrinogen, IL-6, and TNF-α between CKD patients with and without anemia. Serum hepcidin correlated positively with ferritin (r=0.45 p<0.05), TNF-α (r=0.54, p<0.05) and negatively with erythropoietin (r=-0.51, p<0.05). Multiple linear regression analysis demonstrated that TNF-α is an independent predictor of serum hepcidin in our patients (p=0.003, R=0.71). Conclusion: We found no differences in serum hepcidin, erythropoietin and inflammatory markers in non-dialysis CKD patients with and without anemia.
1. Gilbertson D, Peng Y, Bradbury B, Ebben J, Collins A. Hemoglobin level variability: anemia management among variability groups. Am J Nephrol. 2009; 30: 491-498.
2. McClellan W, Aronoff S, Bolton W, Hood S, Lorber D, Tang K, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004; 20: 1501-1510.
3. Astor B, Muntner P, Levin A, Eustace J, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med. 2002; 162: 1401-1408.
4. Kohagura K, Tomiyama N, Kinjo K, Takishita S, Iseki K. Prevalence of anemia according to stage of chronic kidney disease in a large screening cohort of Japanese. Clin Exp Nephrol. 2009; 13: 614-620.
5. Stauffer E, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS ONE. 2014; 9: pe84943.
6. Eschbach J. The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989; 35: 134-148.
7. Zadrazil J, Horak P. Pathophysiology of anemia in chronic kidney diseases: A review. biomed Pap Med Fac Univ Olomouc Czech Repub. 2015; 159: 197-202.
8. Babitt J, Lin H. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012; 23: 1631-1634.
9. Wagner M, Ashby D. Hepcidin-a well-known iron biomarker with prognostic implications in chronic kidney disease. Nephrol Dialysis Transplant. 2013; 28: 2936-2939.
10. Atkinson M, Kim J, Roy C, Warady B, White CT , Furth S. Hepcidin and risk for anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD Cohort. Pediatr Nephrol. 2015; 30: 635-643.
11. Chonchol M, Lippi G, Montagnana M, Muggeo M, Targher G. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. Nephrol Dial Transplant. 2008; 23: 2879-2883.
12. Gupta J, Mitra N, Kanetsky P, Devaney J, Wing M, Reilly M, et al. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012; 12: 1938-1946.
13. Bruck K, Stel V, Gambaro G, Hallan S, Volzke H, Arnloy J, et al. CKD prevalence varies across the European general population. Am J Soc Nephrol. 2015; 27.
14. Chiang C, Tanaka T, Inagi R, Fujita T, Nangaku M. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab Invest. 2011; 91: 1564-1571.
15. Al-Khoury S, Afzali B, Shah N, Thomas S, Gusbeth-Tatomir P, Goldsmith D, et al. Diabetes, kidney disease and anaemia: time to tackle a troublesome triad? Int J Clin Pract. 2007; 61: 281-289.
16. Ramey G, Deschemin J, Durel B, Canonne-Hergaux F, Nicolas G, Vaulont S. Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica. 2010; 95: 510-504.
17. Tsuchiya K, Nitta K. Hepcidin is a potential regulator of iron status in chronic kidney disease. Therapeuric Apheresis and Dialysis. 2013; 17: 1-8.
18. Troutt J, Butterfield A, Konrad R. Hepcidin-25 concentrations are markedly increased in patients with chronic kidney disease and are inversely correlated with estimated glomerular filtration rates. J Clin Lab Analysis. 2013; 27: 504-510.
19. Weiss G, Theurl I, Eder S, Koppelstaetter C, Kurz K, Sonnweber T, et al. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy. Eur J Clin Invest. 2009; 39: 883-890.
20. Malyszko , Malyszko J, Pawlak K, Mysliwiek M. Hepcidin, iron status and renal function in chronic renal failure, kidney transplantation and hemodialysis. Am. J. Hematol. 2006; 81: 832-837.
21. Uehata T, Tomosugi N, Shoji T, Sakaguchi Y, Suzuki A, Kaneko T, et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol. Dial. Transplant. 2012; 27: 1076-1083.
22. Peters H, Laarakkers C, Swinkels D, Wetzels J. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrol. Dial. Transplant. 2010; 25: 848-853.
23. Lukaszyk E, Lukaszyk M, Koc-Zorawska E, Tobolczyk J, Bodzenta- Lukaszyk A, Malyszko J. Iron status and inflammation in early stages of chronic kidney disease. Kidney Blood Press Res. 2015; 40: 366-373.
24. Mercadel L, Metzger M, Haymann J, Thervet E, Boffa J, Flamant M, et al. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PLos One. 2014; 9: e99781.
25. Young B, Zaritsky J. Hepcidin for clinicians. Clin J Am Soc Nephrol. 2009; 4: 1384-1387.
26. Fehr T, Ammann P, Garzoni D, Korte W, Fierz W, Rickji H, et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int. 2004; 66: 1206-1211.
27. Mercadel L, Metzger M, Casadevall N, Haymann J, Karras A, Boffa J, et al. Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol. 2012; 7: 35-42.
28. Camaschella C. Iron-deficiency anemia. N. Engl. J. Med. 2015; 372: 1832- 1843.
29. Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012; 1823: 1434-1443.
30. Rao M, Wong C, Kanetsky P, Girndt M, Sternvinkel P, Reilly M, et al. Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int. 2007; 72: 549-556.
31. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P. Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant. 2003; 18: 1042-1045.
32. Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen B, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin INvest. 2004; 113: 1271-1276.
33. Yang L, Zhang P, Tang F, Wang F, Li E. Correlation between hepcidin level and renal anemia. Genet Mol Res. 2014; 13: 7407-7410.
34. Jairam A, Das R, Aggarwal P, Kohli H, Gupta K, Sakhuja V, et al. Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy. Indian Journal of Nephrology. 2010; 20: 125-131.
35. Gammella E, Diaz V, Recalcati S, Buratti P, Samaja M, Dey S, et al. Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly. Am J Physiol Regul Integr Comp Physiol. 2015; 308: R330-R335.
36. Langdon J, Yates S, Femnou L, McCranor B, Cheadle C. Hepcidindependent and hepcidin-independent regulation of erythropoiesis in a mouse model of anemia of chronic inflammation. Am J Hematol. 2014: 470-479.
37. Song S, Iwahashi M, Tomosugi N, Uno K, Yamana J, Yamana S, et al. Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res Ther. 2013; 15: R141.